Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:16:56.974Z.
Calculation as of: 2026-10-06T19:16:56.974Z.
Quote observation: 2026-10-06T19:15:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b98ba4015092d5f9d3a8f7230bb6a5b98cf1bb4c669b9b66f04bb37649ead8fd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-08-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$63.16M
Price/FCF Ratio
N/A
TTM Avg
47.92
3Y Avg
47.92
5Y Avg
47.92
Market Cap
$61.95M
Price/FCF Ratio
N/A
TTM Avg
1.90
3Y Avg
1.90
5Y Avg
1.90
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | $65.29M | N/A | N/A | N/A | N/A |
| XBiotech Inc. (XBIT)vs › | $66.01M | N/A | 4.54 | 4.54 | 4.54 |
| iBio, Inc. (IBIO)vs › | $66.87M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $66.94M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.56M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.16M | N/A | 47.92 | 47.92 | 47.92 |
| RenovoRx, Inc. (RNXT)vs › | $63.52M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.02M | 8.57 | 6.78 | 6.78 | 131.43 |
| Heron Therapeutics, Inc. (HRTX)vs › | $61.95M | N/A | 1.90 | 1.90 | 1.90 |
| Champions Oncology, Inc. (CSBR)vs › | $69.88M | N/A | 17.09 | 24.44 | 36.17 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2025-08-05 | 53.93 |
| 2025-08-04 | 54.18 |
| 2025-08-01 | 49.94 |
| 2025-07-31 | 50.94 |
| 2025-07-30 | 51.94 |
| 2025-07-29 | 48.94 |
| 2025-07-28 | 49.44 |
| 2025-07-25 | 45.94 |
| 2025-07-24 | 44.44 |
| 2025-07-23 | 46.69 |
| 2025-07-22 | 42.95 |
| 2025-07-21 | 43.70 |
| 2025-07-18 | 42.45 |
| 2025-07-17 | 42.70 |
| 2025-07-16 | 41.45 |
| 2025-07-15 | 36.20 |
| 2025-07-14 | 38.20 |
| 2025-07-11 | 33.96 |
| 2025-07-10 | 33.96 |
| 2025-07-09 | 33.96 |
| 2025-07-08 | 31.71 |
| 2025-07-07 | 31.21 |
| 2025-07-03 | 30.96 |
| 2025-07-02 | 30.21 |
| 2025-07-01 | 31.21 |
| 2025-06-30 | 30.71 |
| 2025-06-27 | 31.21 |
| 2025-06-26 | 32.46 |
| 2025-06-25 | 33.96 |
| 2025-06-24 | 34.46 |
| 2025-06-23 | 34.21 |
| 2025-06-20 | 35.96 |
| 2025-06-18 | 32.21 |
| 2025-06-17 | 30.96 |
| 2025-06-16 | 31.96 |
| 2025-06-13 | 30.96 |
| 2025-06-12 | 31.71 |
| 2025-06-11 | 32.21 |
| 2025-06-10 | 31.21 |
| 2025-06-09 | 33.21 |
| 2025-06-06 | 33.21 |
| 2025-06-05 | 31.46 |
| 2025-06-04 | 31.46 |
| 2025-06-03 | 30.46 |
| 2025-06-02 | 28.96 |
| 2025-05-30 | 27.72 |
| 2025-05-29 | 28.21 |
| 2025-05-28 | 28.96 |
| 2025-05-27 | 27.97 |
| 2025-05-23 | 29.96 |
| 2025-05-22 | 28.96 |
| 2025-05-21 | 28.71 |
| 2025-05-20 | 29.46 |
| 2025-05-19 | 27.22 |
| 2025-05-16 | 25.97 |
